DS Pharma Biomedical Co. starts sales of 3D skin equivalents producing melanin

The melanin-producing Muse cells were produced from autologous iPS cells by a technology developed in Tohoku University’s Clio Co. under a NEDO contract and transferred to DS Pharma Biomedical Co. for commercial exploitation, mainly as a cosmetic test model. Future applications may also be for malignant tumors of the skin.

NEDO news release, Dec. 11., 2014

DS Pharma Biomedical Co. starts sales of 3D skin equivalents producing melanin
Scroll to top